| |
| |
| 체계적 명칭 (IUPAC 명명법) | |
|---|---|
| [(2,3-Dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylamino] methanesulfonic acid | |
| 식별 정보 | |
| CAS 등록번호 |
50567-35-6 68-89-3 (sodium salt) |
| ATC 코드 | N02BB02 |
| PubChem | 3111 |
| 드러그뱅크 | DB04817 |
| ChemSpider | 3000 |
| 화학적 성질 | |
| 화학식 | C13H17N3O4S |
| 분자량 | ? |
| SMILES | eMolecules & PubChem |
| 유의어 | Dipyrone (BAN UK, USAN US) |
| 약동학 정보 | |
| 생체적합성 | 100% (active metabolites) |
| 단백질 결합 | 48–58% (active metabolites) |
| 동등생물의약품 | ? |
| 약물 대사 | Liver |
| 생물학적 반감기 | 14 minutes (parent compound; parenteral); metabolites: 2–4 hours |
| 배출 | Urine (96%, IV; 85%, oral), faeces (4%, IV). |
| 처방 주의사항 | |
| 임부투여안전성 | None assigned; no evidence of teratogenicity in animal studies, but use in the third trimester may cause adverse effects in the newborn or ductus arteriosus (a heart defect) due to its weak NSAID activity. |
| 법적 상태 | Over-the-counter (some countries, see text); prescription-only (others); withdrawn (others) |
| 투여 방법 | Oral, IM, IV, rectal |